Greetings, and welcome to the HeartBeam Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important facts relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wire this afternoon and is available in the Investor Relations section of our website, heartbeam.com. Your host today is Branislav Vajdic, Chief Executive Officer and Founder; Rob Eno, President; and Ravi Malhotra, Senior Director and Corporate Controller, who will present results of operations for the second quarter ended June 30, 2024. At this time, I will turn the call over to HeartBeam Chief Executive Officer, Branislav Vajdic. Please go ahead.

Thank you, operator. I want to begin by highlighting the vision for HeartBeam's innovative technology. HeartBeam is working on AIMIGo, a compact, cable-free cardiac monitoring device that can generate a 12-Lead ECG using the company's core vector technology, which captures a complete range of signals from the heart's electrical activity. AIMIGo has the potential to create new applications for both patients and healthcare providers, including the detection of heart attacks at the onset of symptoms, identifying complex arrhythmias that current devices cannot pick up, and monitoring chronic conditions like heart failure, as well as enabling prevention and screening through AI. Furthermore, HeartBeam has extensive intellectual property protection on its core technologies and innovative forms. These include applying our vector technology to a prolonged wear cardiac monitor or a mobile cardiac telemetry device, introducing on-demand 12-lead ECG technology to the market with reimbursement, and developing a unique watch format that combines continuous monitoring with a 12-lead on-demand wrist-worn device. As previously stated, 12-lead ECG is among the most frequently conducted diagnostic tests and is the standard procedure in medical facilities. There are various ECG technologies available for patients or consumers to use at home, some of which are displayed on this slide. However, they do not constitute 12-lead ECGs; they are instead 1-lead, 3-lead, or 6-lead devices. While these might be sufficient for identifying many arrhythmias, they are inadequate for detecting heart attacks or complex arrhythmias. In contrast, HeartBeam AIMIGo is a user-friendly, cable-free, credit card-sized system that synthesizes a 12-lead ECG. The primary goal of HeartBeam technology is to assist clinicians in swiftly and accurately identifying a full spectrum of cardiac conditions, including heart attacks outside of a healthcare setting. Currently, patients experiencing heart attacks tend to wait an average of 3 to 4 hours before seeking medical help, which can result in fatalities and serious complications like heart failure. Next, we would like to show a video that illustrates how straightforward it will be for patients to utilize AIMIGo in everyday settings. Please note that those of you on the phone will not hear the audio, resulting in about 50 seconds of silence. And now I will pass the call to HeartBeam President, Rob Eno.

Thank you, Branislav. HeartBeam technology has the potential to transform a large number of markets. Initially, we'll focus on the detection of arrhythmias with AIMIGo, where its 12-lead capabilities and advanced AI could outperform existing ambulatory cardiac ECGs. Expansion into heart attack detection, where 12-lead is needed, accesses the 20 million patients with coronary artery disease and is a $12 billion opportunity. Incorporating our proprietary technology into the patch market accesses a market with established reimbursement that's estimated to grow to $4.8 billion in 2030. Over time, HeartBeam's technology plus AI can move into monitoring for the management of chronic conditions such as heart failure and chronic kidney disease, where 12-lead ECG, coupled with deep learning algorithms, could provide valuable insights. Ultimately, a simple, easy-to-use 12-lead device with predictive algorithms could be a prevention and screening tool for an even larger set of patients. More than 120 million Americans have some form of heart disease. We're incredibly excited about the long-term potential of the technology. In addition, we're making steady progress on our near-term milestones. Our initial clearance for the AIMIGo system will be a major milestone for the company and is important for several reasons. To start, we anticipate this will be the first patient-held device leveraging vector technology to be cleared by the FDA. Also, this clearance will be the basis for further FDA submissions for HeartBeam, so it's the cornerstone of our efforts. The vector approach is an excellent platform for AI algorithms. In the longer run, we believe that applying AI algorithms on top of the rich 360-degree signals could result in unsurpassed predictive and diagnostic capabilities. Our 510(k) submission for the AIMIGo system is currently under review by the agency. We are in the substantial review phase of answering questions posed by the FDA on this submission. We have successfully resolved the vast majority of the questions the FDA has asked. Since our last update, the FDA requested additional information, which we're in the process of providing. The company is working with the FDA to address the small number of remaining questions. We continue to be engaged in productive discussions with the agency, and we believe that we're progressing toward clearance. The company continues to plan for a limited launch of AIMIGo by the end of 2024, which will provide us with valuable feedback on the user experience and functionality of the system in a real-world setting. We continue to make significant progress on other fronts. We're preparing materials for our second FDA 510(k) submission on the algorithms that convert the 360-degree signals captured by the AIMIGo system into a synthesized 12-lead ECG. On June 20, we completed enrollment in VALID-ECG, the 198-patient trial comparing simultaneously placed AIMIGo and 12-lead ECGs. We completed enrollment in just 3 months, which is extremely fast for a study of this size. The data are currently being analyzed. VALID-ECG will be the basis of the 12-lead synthesis submission, and we anticipate filing this submission soon after we receive clearance for the AIMIGo system. Prior to enrolling VALID-ECG, we conducted an 80-patient pilot study utilizing the same protocol. That study has been accepted for presentation at the American Heart Association meeting in November. We've also made great progress on our AI program. In Q2, there were scientific presentations at two top electrophysiology conferences that demonstrate the ability of HeartBeam's AI to detect atrial flutter, an important arrhythmia that's difficult to identify with a single lead ECG. These studies demonstrated that HeartBeam's AI algorithm applied to vector cardiography or VCG greatly outperformed AI on a single lead ECG. Also, HeartBeam's AI algorithm applied to VCG outperformed both an expert panel of electrophysiologists reviewing single lead ECGs and impressively an expert panel reviewing 12-lead ECGs with a statistically significant improvement in the detection of atrial flutter cases. The development of the AI algorithms has progressed. We're getting close to freezing our multiple AI models powering HeartBeam AI that once cleared by the FDA will provide a comprehensive set of diagnostic suggestions. This powerful AI-based tool, combined with the 12-lead ECG provided to the cardiologist, will, we believe, offer beyond anything currently available in patient-obtained ECGs, both in terms of diagnostic coverage and accuracy. We've gained significant experience with AIMIGo and believe that technology is de-risked. We've conducted multiple clinical studies enrolling more than 500 patients. These include the VALID-ECG study described previously, as well as the 80-patient pilot study. We've previously discussed the study published last year in JAK Advances demonstrating equivalence to 12-lead ECG in detecting coronary occlusions and also showing a significant improvement in accuracy when comparing the HeartBeam approach with a baseline report from a single 12-lead ECG, which is often the case in emergency rooms. We've completed another study on the performance of our ECG technology together with symptoms and patient history compared to the standard of care. These results will also be presented at the American Heart Association meeting in November, along with the results of the 12-lead synthesis pilot study mentioned earlier. A total of two presentations at this strategic scientific conference later this year. Beyond the clinical protocols, we have usability experience in a real-world setting with over 7,500 recordings for more than 250 patients, providing us with strong confidence in the system's functionality. I'd now like to hand the call over to our Corporate Controller, Ravi Malhotra, to present selected financials.

Thank you, Rob. I'll now give a brief overview of our financial results. A full breakdown is available in our regulatory filings and in the press release that crossed the wire after market close today. General and administrative expenses for the second quarter of 2024 were $2.2 million compared to $1.8 million for the second quarter of 2023. The increase in G&A expense is primarily related to noncash stock-based compensation expense associated with additional awards granted since June 30, 2023, and also higher consulting costs, primarily offset by lower legal costs in the current period. Research and development expenses for the second quarter of 2024 were $2.8 million compared to $1.5 million for the second quarter of 2023. The increase in R&D expense is primarily related to an increase in headcount, as well as clinical and AI-related costs and an increase in consulting spending, which is offset by a decrease in product development consulting costs, primarily driven by completion of milestone projects in the prior period. Net loss for the second quarter of 2024 was $5 million compared to a net loss of $3.2 million for the second quarter of 2023. We ended the quarter with approximately $9.2 million in cash and cash equivalents as we closed in on carefully managed spending. I will now turn the call back to Branislav for closing thoughts.

In conclusion, we remain extremely excited about the potential at HeartBeam and our progress. AIMIGo will be the smallest, easiest to use, and the first cable-free 12-lead ECG device enabled by HeartBeam's unique IP-protected vector technology. It has the potential to disrupt numerous large markets and clinical applications, starting with the ability to detect complex arrhythmias, expanding to heart attack detection and then to monitoring for complex diseases such as heart failure. Ultimately, we believe that the combination of the small form factor, powerful 360-degree ECG technology, and advanced AI algorithms will have significant applications in prediction and screening of cardiac conditions. We continue to make progress towards key regulatory and clinical milestones. Our initial 510(k) application for the AIMIGo system is under active FDA review with productive discussions underway. The company is working with the FDA to address a small number of remaining questions. We believe that we are progressing towards clearance. We anticipate a limited launch by the end of the year, focused on the AIMIGo system, which will provide the company with valuable feedback on the user experience and functionality of the system in a real-world setting. We are preparing materials for our second FDA submission, which will be a 510(k) submission on the algorithms that convert the vector signal captured by our AIMIGo system into a synthesized VALID-ECG. We have completed enrollment in the VALID-ECG study and anticipate submitting the 510(k) application soon after the clearance of the AIMIGo system. We presented positive new data on our deep learning algorithm HeartBeam AI, demonstrating excellent performance in detecting atrial flutter, even outperforming a panel of three electrophysiologists reviewing 12-lead ECG. We are working to freeze the algorithms in preparation for a clinical study to demonstrate the performance of our AI algorithms. We ended the quarter with approximately $9.2 million in cash and cash equivalents, enabling the company to execute on upcoming clinical and regulatory milestones. I look forward to providing our shareholders with further updates in the near term. I thank you all for attending. Now the HeartBeam team would like to answer your questions.

We will now begin the question-and-answer session. Currently, I do not see any questions on the phone.

Our first webcast question. Can you just provide some more detail on the timing of the FDA clearance?

Yes. Let me comment on that. We are under active review with the FDA, and we really can't give any more details than what we said in the call and in our earnings materials. To reiterate, we have successfully resolved the vast majority of the questions the FDA has asked. Last quarter, the FDA requested additional information, which we are now in the process of providing. We are engaged in productive discussions with the FDA and believe that we are progressing towards clearance. We still anticipate a limited launch before the end of the year. Again, this will provide us with valuable feedback on the user experience as well as the functionality of the system in the real-world setting, extremely valuable to us.

Thank you. Let's see. Our next question. You showed market sizes for HeartBeam's technology. Can you explain just where you're going with those?

Sure. Yes, thanks. That was a new framework. So I can elaborate. The main point there really is to show that HeartBeam's technology, which is again a credit card-sized cable-free device that produces a 12-lead ECG, can have a wide range of applications. So it's a progression. We're starting with what we call symptom-driven diagnosis, which is arrhythmia, then moving on to ischemia and heart attack detection. We also have the ability to incorporate the technology into an extended wear patch monitor that can provide for on-demand 12-week capabilities. With both that form factor and with AIMIGo itself, we think that could move us into monitoring for patients with chronic conditions like heart failure and chronic kidney disease. Ultimately, beyond that, we think that patients taking frequent 12-lead ECGs over time, especially when combined with AI algorithms, can enable prevention and screening for a very large number of patients. So it really shows the progression with sample segments from symptom-driven diagnosis through monitoring into prevention and screening.

Thanks. Our next question. You mentioned that the VALID-ECG study has completed enrollment. What are the results of the study?

Yes, Rob, please shed some light on that.

Sure. So first, as a reminder, VALID-ECG was a study with simultaneously collected ECGs. So the patient had both a standard 12-lead ECG and AIMIGo at the same time. The goal was to demonstrate the similarity between the standard 12-lead signals and our synthesized 12-lead signals. We have had two pre-submission meetings with the FDA that are largely focused on the endpoints of the study. So where we are right now is we've completed enrollment back in June, as I mentioned, but the data is currently being analyzed. So the results are not available. We do anticipate completing that analysis soon, as that will be the basis for the second FDA submission that we plan to submit shortly. I would note that we did complete this 80-patient pilot study with the same protocol. We can't say the results of that because it's been accepted for a presentation in November at the American Heart Association. But based on the results of those studies, we did proceed with VALID-ECG.

Great. Thank you. The next question, if the 12-lead ECG is being evaluated by a physician, why do you need AI?

Yes. Let me answer that question. Our vision is that with HeartBeam AI, the user will get an automated arrhythmia classification, and that's going to happen immediately after every use. However, of course, it is important that a physician reviews the complete clinical picture, which includes the ECG. We actually anticipate having two workflows here. If the user is experiencing symptoms, the ECG will be automatically sent to the user's physician or to a physician monitoring service for evaluation. On the other hand, if the user is not experiencing symptoms but is taking a routine recording to add to their database of ECGs, the ECG will not automatically go to a physician for interpretation. This is for asymptomatic recording, but the user will have the option to do so. In either case, symptomatic or not symptomatic, AI will play a key role in informing the patient and helping physicians diagnose the patient.

Great. Thanks. Next question. Will the initial AIMIGo product be able to detect heart attacks from the get-go? Or will there need to be further R&D before that claim can be made?

We have actually done a lot of research, and we've conducted two studies related to heart attack detection. So in terms of the development, there is still some work to do. But fundamentally, we believe that we have a technology that's going to provide leading insight into patients with chest pain. So overall, at this point, we are focusing on arrhythmia detection, especially complex arrhythmias that other technologies cannot detect. Our plan is, as soon as that is productized and in the marketplace, we will apply all our resources to enable the product to detect heart attacks.

Thanks. Next question, is it possible to speak to pursuing FDA approval for atrial flutter versus atrial fibrillation?

Yes. You want me to take that one, Branislav?

Yes, go ahead.

Yes, it's just similar to what Branislav said before, we're taking a stepwise approach with FDA. The initial indications are for arrhythmia and cover a range of arrhythmias. So those do encompass atrial flutter and atrial fibrillation, and we'll have clinical data on that. So yes, pursuing those is within the scope of the initial clearance.

Great. That is the final question there. I'll turn now the call back over to Dr. Vajdic for his closing remarks.

Thank you, operator. I would like to thank each of you for joining our earnings conference today and look forward to continuing to update you on our ongoing progress and growth. If you were not able to have any of your questions answered today, please reach out to our IR firm, MZ Group, who would be more than happy to assist. Thank you again.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.